Iqbal Faruqui
Internal Medicine · Blountstown, FLNPI 1841267010
Payments from drug & device makers
Across 171 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$488
- AstraZeneca$261
- Astellas Pharma US Inc$246
- Amgen$218
- Bayer$195
- AbbVie$149
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,65296%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $488 |
| AstraZeneca | 19 | $261 |
| Astellas Pharma US Inc | 11 | $246 |
| Amgen | 13 | $218 |
| Bayer | 11 | $195 |
| AbbVie(2 entities) | 8 | $149 |
| Sunovion Pharmaceuticals Inc. | 9 | $142 |
| Avanir Pharmaceuticals, Inc. | 9 | $140 |
| Lilly USA, LLC | 8 | $125 |
| Pfizer | 6 | $85 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| GSK | 4 | $70 |
| Novartis | 5 | $66 |
| Biogen | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Organogenesis Inc. | 2 | $48 |
| Dexcom, Inc. | 2 | $47 |
| Boehringer Ingelheim | 3 | $45 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $34 |
| Exact Sciences | 2 | $34 |
| Melinta Therapeutics, LLC | 2 | $33 |
| Almatica Pharma LLC | 1 | $32 |
| Merck | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
How this compares
$2,751 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 391 | $172,361 |
| JardianceEmpagliflozin | 136 | $105,976 |
| OzempicSemaglutide | 75 | $97,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $89,855 |
| FarxigaDapagliflozin Propanediol | 90 | $69,019 |
| TradjentaLinagliptin | 73 | $40,892 |
| JanuviaSitagliptin Phosphate | 54 | $38,835 |
| GlyxambiEmpagliflozin/Linagliptin | 29 | $32,995 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $30,754 |
| LinzessLinaclotide | 43 | $30,631 |
| MyrbetriqMirabegron | 30 | $29,270 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $27,671 |
| RexultiBrexpiprazole | 20 | $27,260 |
| EntrestoSacubitril/Valsartan | 43 | $27,244 |
| NamzaricMemantine Hcl/Donepezil Hcl | 55 | $26,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $45 | $179,862238 claims |
| PfizerEliquis | $85 | $172,361391 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $70 | $117,140167 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $261 | $98,932159 claims |
| Novo NordiskOzempic | $488 | $97,70375 claims |
| MerckJanuvia, Janumet | $18 | $69,58984 claims |
| AbbVieLinzess, Namzaric | $149 | $57,14498 claims |
| Lilly USA, LLCMounjaro, Trulicity | $125 | $42,55135 claims |
| Astellas Pharma US IncMyrbetriq | $246 | $29,27030 claims |
| NovartisEntresto | $66 | $27,24443 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $140 | $26,11755 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $142 | $17,19328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Blountstown
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.